| Abstract |
The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly. There have recently been publications in the literature regarding the relationship between COVID-19 and Kawasaki disease, but there is no sufficient knowledge about the treatment and follow-up. |
| Authors | Zerrin Orbak, Fuat Laloglu, Hulya Akat |
| Journal | Cardiology in the young
(Cardiol Young)
Vol. 31
Issue 3
Pg. 507-510
(Mar 2021)
ISSN: 1467-1107 [Electronic] England |
| PMID | 33183365
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Anti-Bacterial Agents
- Anticoagulants
- Antiviral Agents
- Drug Combinations
- Enoxaparin
- Immunoglobulins, Intravenous
- Immunologic Factors
- lopinavir-ritonavir drug combination
- Oseltamivir
- Lopinavir
- Hydroxychloroquine
- sultamicillin
- Ampicillin
- Azithromycin
- Ritonavir
- Sulbactam
|
| Topics |
- Ampicillin
(therapeutic use)
- Anti-Bacterial Agents
(therapeutic use)
- Anticoagulants
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- Azithromycin
(therapeutic use)
- COVID-19
(complications, diagnostic imaging, physiopathology)
- COVID-19 Nucleic Acid Testing
- COVID-19 Serological Testing
- Child
- Drug Combinations
- Enoxaparin
(therapeutic use)
- Humans
- Hydroxychloroquine
(therapeutic use)
- Hypoxia
(etiology, physiopathology, therapy)
- Immunoglobulins, Intravenous
(therapeutic use)
- Immunologic Factors
(therapeutic use)
- Lopinavir
(therapeutic use)
- Lung
(diagnostic imaging)
- Male
- Mucocutaneous Lymph Node Syndrome
(drug therapy, etiology, physiopathology)
- Oseltamivir
(therapeutic use)
- Oxygen Inhalation Therapy
- Ritonavir
(therapeutic use)
- Sulbactam
(therapeutic use)
- Tomography, X-Ray Computed
- COVID-19 Drug Treatment
|
